Home > Insider Trading > Filing (0001104659-16-131409)

Filing Details

Accession Number:: 0001104659-16-131409
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-07-07 06:02:33
Reporting Period:: 2016-07-06

Filing Date:: 2016-07-07
Accepted Time:: 2016-07-07 06:02:33
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1556263	Syros Pharmaceuticals Inc.	SYRS	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1219039	Keith Crandell	8755 West Higgins Road, Suite 1025 Chicago IL 60631	No	No	Yes	No
1219043	Clinton Bybee	8755 West Higgins Road, Suite 1025 Chicago IL 60631	No	No	Yes	No
1402439	Arch Venture Fund Vii Lp	8755 West Higgins Road, Suite 1025 Chicago IL 60631	No	No	Yes	No
1544443	Arch Venture Partners Vii, Llc	8755 West Higgins Road, Suite 1025 Chicago IL 60631	No	No	Yes	No
1544444	Arch Venture Partners Vii, L.p.	8755 West Higgins Road, Suite 1025 Chicago IL 60631	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2016-07-06	266,666	$0.00	479,999	No	4	C	Direct
Common Stock	Acquisiton	2016-07-06	1,333,333	$0.00	1,813,332	No	4	C	Direct
Common Stock	Acquisiton	2016-07-06	2,000,000	$0.00	3,813,332	No	4	C	Direct
Common Stock	Acquisiton	2016-07-06	423,805	$0.00	4,237,137	No	4	C	Direct
Common Stock	Acquisiton	2016-07-06	400,000	$12.50	4,637,137	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A-1 Preferred Stock	Disposition	2016-07-06	1,000,000	$0.00	266,666	$0.00
Common Stock	Series A-2 Preferred Stock	Disposition	2016-07-06	5,000,000	$0.00	1,333,333	$0.00
Common Stock	Series A-3 Preferred Stock	Disposition	2016-07-06	7,500,000	$0.00	2,000,000	$0.00
Common Stock	Series B Preferred Stock	Disposition	2016-07-06	1,589,269	$0.00	423,805	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct

Footnotes

The Series A-1 Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
The Series A-2 Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
The Series A-3 Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-3 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
The Series B Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
These shares are owned directly by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"). The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"). The Managing Directors of ARCH VII LLC, Robert T. Nelsen, Keith Crandell and Clinton Bybee, are deemed to have voting and dispositive power over the shares and may be deemed to beneficially own certain shares held by ARCH Fund VII. Each Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of such securities for Section 16 or any other purpose.